Albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
== Personal life == Woolley married bacteriologist Janet Ruth McCarter in 1945. Woolley had Diabetes mellitus type 1 from childhood, and in 1923 was among the first children to receive insulin to treat the condition. He nonetheless experienced blindness as a complication of his diabetes, and was completely blind from age 25 until his death from a heart attack at age 52, while hiking in Cuzco, Peru.
== External links == Die Geschichte des Wirkstoffs Cyproteronazetat: Von der "Pille für den Mann" zum "Hautpflegemittel mit Empfängnisschutz" [The History of Cyproterone Acetate: From the "Pill for Men" to the "Skin Care Product and Contraceptive"] - Arznei-Telegramm (in German) [Google Translate]
An aquaretic is a novel class of drug that is used to promote aquaresis, the excretion of water without electrolyte loss. Strictly speaking, aquaretics are not diuretics but are sometimes classified as such. Aquaresis is preferable to diuresis in the treatment of hyponatremia.
Sources: en.wikipedia.org
== L == Lac repressor – lactic acid autotroph – lagging strand – lambda phage – larva – leading strand – leaf – White blood cells – lichen – life form – life – light reactions – limbic system – limnology – Lineweaver-Burk diagram – lipase – lipid – liver – locus – long-term potentiation – Louis Pasteur – lung – Lynn Margulis – Lyon hypothesis – lysis – lysozyme – lytic cycle
==== Swearing-in ceremony controversy ==== On 1 January 2025, Melo and his vice-mayor, Betina Worm of the Liberal Party (PL), took office during the swearing-in ceremony of the Municipal Chamber of Porto Alegre as the city council members were also sworn in. Melo generated controversy by stating that "defenders of the Brazilian military dictatorship should not be prosecuted because this would represent freedom of expression", and also affirmed that "defenders of socialism and communism do not deserve to be punished." Opposition parties would go on to publicly protest against Melo for these comments.
=== 3-MCPD === 3-MCPD, a carcinogen in rodents and a suspected human carcinogen, is created during acid-hydrolysis as glycerol released from lipid (e.g. triglycerides) reacts with hydrochloric acid. Legal limits have been set to keep aHVP products safe for human consumption. aHVP manufacturers can reduce the amount of 3-MCPD to acceptable limits by (1) careful control of reaction time and temperature (2) timely neutralization of hydrochloric acid, optionally extending to an alkaline hydrolysis step to destroy any 3-MCPD already formed (3) replacement of hydrochloric acid with other acids such as sulfuric acid.
Sources: en.wikipedia.org
== Career == Assistant to the chair of physical chemistry at Moscow State University. Research associate at York University Senior scientist at MDS SCIEX Associate professor at UofT in IBBME (2005–2008) and chemistry (2008–2011). Adjunct professor at York University. Principal scientist at DVS Sciences - 2005–2019 (acquired by Fluidigm in 2014 and then Standard BioTools in 2022)
These findings suggest specific parasite loci may be under vaccine-induced immune pressure and highlight potential targets for future optimization of whole-sporozoite vaccines. PfSPZ Vaccine development has been closely linked with malaria elimination efforts on Bioko Island, Equatorial Guinea. By 2024–2025, a series of registry studies, incidence surveys and dose-optimization trials had been completed as part of preparations for a large-scale, Africa-led phase 3 efficacy trial. These activities were coordinated through the Equatoguinean Malaria Vaccine Initiative, which aims to evaluate PfSPZ Vaccine in a setting with intense seasonal transmission and established malaria control programs.
=== Morphological instabilities === In an ideal world, the spatial concentration of particles within the SSZ would remain constant throughout solidification. As it happens, though, the concentration of particles does change during compression, and this process is highly sensitive to solidification speed. At low freezing rates, Brownian motion takes place, allowing particles to move easily away from the solid-liquid interface and maintain a homogeneous suspension. In this situation, the suspension is always warmer than the solidified portion. At fast solidification speeds, approaching VC, the concentration, and concentration gradient at the solid-liquid interface increases because particles cannot redistribute soon enough. When it has built up enough, the freezing point of the suspension is below the temperature gradient in the solution and morphological instabilities can occur. For situations where the particle concentration bleeds into the diffusion layer, both the actual and freezing temperature dip below the equilibrium freezing temperature creating an unstable system. Often, these situations lead to the formation of what are known as ice lenses. These morphological instabilities can trap particles, preventing full redistribution and resulting in inhomogeneous distribution of solids along the freezing direction as well as discontinuities in the ceramic walls, creating voids larger than intrinsic pores within the walls of the porous ceramic.
=== EC 2.7.4: Phosphotransferases with a phosphate group as acceptor === EC 2.7.4.1: ATP-polyphosphate phosphotransferase EC 2.7.4.2: phosphomevalonate kinase EC 2.7.4.3: adenylate kinase EC 2.7.4.4: nucleoside-phosphate kinase EC 2.7.4.5: deleted, now included with EC 2.7.4.14 cytidylate kinase EC 2.7.4.6: nucleoside-diphosphate kinase EC 2.7.4.7: phosphomethylpyrimidine kinase EC 2.7.4.8: guanylate kinase EC 2.7.4.9: dTMP kinase EC 2.7.4.10: nucleoside-triphosphate—adenylate kinase EC 2.7.4.11: (deoxy)adenylate kinase EC 2.7.4.12: T2-induced deoxynucleotide kinase EC 2.7.4.13: (deoxy)nucleoside-phosphate kinase EC 2.7.4.14: cytidylate kinase EC 2.7.4.15: thiamine-diphosphate kinase EC 2.7.4.16: thiamine-phosphate kinase EC 2.7.4.17: 3-phosphoglyceroyl-phosphate—polyphosphate phosphotransferase EC 2.7.4.18: farnesyl-diphosphate kinase EC 2.7.4.19: 5-methyldeoxycytidine-5′-phosphate kinase EC 2.7.4.20: dolichyl-diphosphate—polyphosphate phosphotransferase EC 2.7.4.21: inositol-hexakisphosphate kinase EC 2.7.4.22: UMP kinase EC 2.7.4.23: ribose 1,5-bisphosphate phosphokinase EC 2.7.4.24: diphosphoinositol-pentakisphosphate kinase EC 2.7.4.25: (d)CMP kinase EC 2.7.4.26: isopentenyl phosphate kinase EC 2.7.4.27: [pyruvate, phosphate dikinase]-phosphate phosphotransferase EC 2.7.4.28: [pyruvate, water dikinase]-phosphate phosphotransferase EC 2.7.4.29: Kdo2-lipid A phosphotransferase EC 2.7.4.30: Now EC 2.7.8.43, lipid A phosphoethanolamine transferase EC 2.7.4.31: [5-(aminomethyl)furan-3-yl]methyl phosphate kinase EC 2.7.4.32: farnesyl phosphate kinase EC 2.7.4.33: AMP-polyphosphate phosphotransferase EC 2.7.4.34: GDP-polyphosphate phosphotransferase
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.